Fighting Patient Infection

Rapid, Sensitive, and Affordable Testing

First Light Biosciences News

News

Recent News

  • May 2016 – First Light is one of two Massachusetts companies to win a Mass Life Science Center Accelerator loan for $750,000. Press release
  • October 2015 – First Light signs a contract with the Biomedical Advanced Research and Development Authority to develop rapid, sensitive, and easy-to-use anthrax tests. The contract supports the project with $5.5 million over 16 months and up to a total of $42.9 million over 6 years if all options are exercised. More Information
  • October 2015 – First Light hires Fred Farber as Chief Product Development Officer.
  • October 2015 – First Light appoints Jeff Arnold as Chairman of the Board.
  • September 2015 – First Light closes a $3.5M Series A financing.
  • February 2015 – First Light awarded $4M 4 year NIH RO1 award for developing tests for rapidly detecting hospital infections and determining the right antibiotic to cure them.
  • December 2013 – European patent granted: “Method for detecting analytes”, Pat. Number 2340300
  • Sept 2011 – US patent issued: “Rapid and sensitive detection of cells and viruses”, Pat. Number US 8021848
  • March 2011 – First Light awarded a $3M 3 year Phase II NIH SBIR grant to develop an benchtop automated platform for hospital clinical microbiology laboratories that rapidly, affordably, and sensitively detects the microbes that cause hospital infections including resistant (MRSA) and sensitive Staphylococcus aureus.
  • June 2010 – European patent granted: “Rapid and sensitive detection of molecules”, Pat. Number 1428010.
  • September 2009 – Filed patent applications for consumables, methods, and instrumentation.
  • March 2009 – First Light awarded a $3M 3 year Phase II NIH SBIR grant to develop an automated platform to accommodate the surge in testing that would occur following a large biowarfare attack or infectious disease outbreak.
  • September 2008 – First Light awarded a $600K 2 year NIH Phase I SBIR grant to develop the MultiPath imaging technology for rapid, sensitive, and low-cost detection of resistant (MRSA) and sensitive Staphylococcus aureus.
  • August 2008 – First Light awarded a $300K NIH Phase I SBIR grant to develop the MultiPath imaging technology for highly sensitive detection of respiratory viruses and to develop a very easy to use instrument model.